Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019

Corporate 16 April 2025 6 mins read

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Corporate 08 April 2025 4 mins read

Ipsen publishes its 2024 Universal Registration Document

Corporate 19 March 2025 7 mins read

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Corporate 12 March 2025 5 mins read

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Corporate 13 February 2025 6 mins read

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

Corporate 03 December 2024 6 mins read

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Corporate 18 November 2024 12 mins read

Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS

Corporate 15 November 2024 12 mins read

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Corporate 23 October 2024 4 mins read

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

Corporate 14 October 2024 5 mins read

Ipsen receives its second Shingo Prize for operational excellence